These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31889617)

  • 1. PAK1 expression determines poor prognosis and immune evasion in metastatic renal cell carcinoma patients.
    Qu Y; Lin Z; Qi Y; Qi Y; Chen Y; Zhou Q; Zeng H; Liu Z; Wang Z; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Zhu Y; Xu L; Chen L; Zhang P; Zhang W; Dai B; Liu L; Xu J; Guo J
    Urol Oncol; 2020 Apr; 38(4):293-304. PubMed ID: 31889617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
    Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
    J Urol; 2016 Nov; 196(5):1363-1370. PubMed ID: 27288695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients.
    Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
    Cancer Immunol Immunother; 2018 Jan; 67(1):79-87. PubMed ID: 28918459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.
    Xia Y; Liu L; Xiong Y; Bai Q; Wang J; Xi W; Qu Y; Xu J; Guo J
    BMC Cancer; 2017 Jan; 17(1):70. PubMed ID: 28114889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p21-activated kinase 1 predicts recurrence and survival in patients with non-metastatic clear cell renal cell carcinoma.
    Zhu Y; Xu L; An H; Liu W; Wang Z; Xu J
    Int J Urol; 2015 May; 22(5):447-53. PubMed ID: 25711487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma.
    Liu L; Xiong Y; Xi W; Wang J; Qu Y; Lin Z; Chen X; Yao J; Xu J; Guo J
    Oncotarget; 2017 Feb; 8(9):14995-15003. PubMed ID: 28122358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor.
    Cai W; Wang Z; Cai B; Yuan Y; Kong W; Zhang J; Chen Y; Liu Q; Huang Y; Huang J; Xue W
    Int J Clin Oncol; 2020 Feb; 25(2):338-346. PubMed ID: 31720994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-infiltrating CD39
    Qi Y; Xia Y; Lin Z; Qu Y; Qi Y; Chen Y; Zhou Q; Zeng H; Wang J; Chang Y; Bai Q; Wang Y; Zhu Y; Xu L; Chen L; Kong Y; Zhang W; Dai B; Liu L; Guo J; Xu J
    Cancer Immunol Immunother; 2020 Aug; 69(8):1565-1576. PubMed ID: 32306075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Genetic Polymorphism in
    Liu X; Swen JJ; Diekstra MHM; Boven E; Castellano D; Gelderblom H; Mathijssen RHJ; Vermeulen SH; Oosterwijk E; Junker K; Roessler M; Alexiusdottir K; Sverrisdottir A; Radu MT; Ambert V; Eisen T; Warren A; Rodríguez-Antona C; García-Donas J; Böhringer S; Koudijs KKM; Kiemeney LALM; Rini BI; Guchelaar HJ
    Clin Cancer Res; 2018 May; 24(10):2350-2356. PubMed ID: 29490989
    [No Abstract]   [Full Text] [Related]  

  • 11. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 12. Preoperative apolipoprotein B/A1 ratio is an independent prognostic factor in metastatic renal cell carcinoma.
    Zhang F; Xie Y; Ma X; Gu L; Li H; Li X; Guo G; Zhang X
    Urol Oncol; 2019 Mar; 37(3):184.e9-184.e17. PubMed ID: 30509867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
    Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
    Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lactate Dehydrogenase-to-Lymphocyte Ratio Represents a Powerful Prognostic Tool of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors.
    Li T; Li H; Xie S; Tan Y; Xie ZP; Li WY; Ai F
    Pathol Oncol Res; 2020 Apr; 26(2):1319-1324. PubMed ID: 31388933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma.
    Chen X; Liu L; Wang J; Lin Z; Xiong Y; Qu Y; Wang Z; Yang Y; Guo J; Xu J
    Urol Oncol; 2018 May; 36(5):242.e15-242.e21. PubMed ID: 29370961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
    Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
    Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma.
    Xiong Y; Liu L; Wang J; Xi W; Xia Y; Bai Q; Qu Y; Long Q; Xu J; Guo J
    Oncotarget; 2017 Apr; 8(15):25650-25659. PubMed ID: 27783999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
    Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
    Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
    Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
    Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma.
    Xie H; Zhu Y; An H; Wang H; Zhu Y; Fu H; Wang Z; Fu Q; Xu J; Ye D
    Oncotarget; 2016 May; 7(22):32723-30. PubMed ID: 27092876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.